2021 AACC Annual Scientific Meeting to Require Both Proof of COVID-19 Vaccination and Negative Test from All In-Person Attendees
|
By LabMedica International staff writers Posted on 31 Aug 2021 |

Illustration
The 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting & Clinical Lab Expo will be a live event with new location and dates, backed by plans to make the meeting a safe and productive one amidst the flare up in the COVID-19 pandemic.
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more









